


IN THE CLAIMS:

Claims 1-14 (Canceled)

Claim 15. (Currently Amended) An insulin analogue consisting of two identical or different insulin monomers covalently linked together via a bridge,

wherein the insulin monomers are selected from a group consisting of comprising a human insulin, an animal insulin insulins, a derivative of a human insulin, and a derivative of an derivatives of human insulin and animal insulin insulins,

wherein at least one derivative of a human insulin or a derivative of an animal insulin is present in said [[an]] insulin analogue, wherein said insulin analogue has a formula of:

wherein:

- a) X is, independently of one another, a branched or unbranched C<sub>1</sub>-C<sub>10</sub>-alkyl group, a mono- or polysubstituted aryl group, a C<sub>1</sub>-C<sub>10</sub>-alkyl group, mono- or polysubstituted or unsubstituted O-aryl group, an amino acid or a derivative thereof, or a group of the formula NRR', wherein
- b) each of R and R' is H, NH<sub>2</sub>, a branched or unbranched C<sub>1</sub>-C<sub>10</sub>-alkyl radical, or a

mono- or polysubstituted or unsubstituted aryl group, and wherein

c) n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16,

or a physiologically acceptable salt of said insulin analogue salts thereof.

Claim 16 (Canceled)

Claim 17. (Currently Amended). The insulin analogue as claimed in claim 16, wherein X is an amino acid in which the carboxylic group of said amino acid is amidated.

Claim 18. (Previously Presented). The insulin analogue as claimed in claim 17, wherein X is the amino acid sarcosine.

Claim 19. (Previously Presented). The insulin analogue as claimed in claim 16, wherein the X residues in the two B chains are different from one another.

Claim 20. (Previously Presented). The insulin analogue as claimed in claim 16, wherein X is an amino group.

Claim 21. (Previously Presented) B1, B1'-Sub-[Sar<sup>B26</sup>]-des-(B27-B30)-insulin-B26-amide insulin dimer.

Claim 22. (Previously Presented) B1, B1'-Sub-[D-Ala<sup>B26</sup>]-des-(B27-B30)-insulin-B26-amide insulin dimer.

Claim 23. (Previously Presented) B1, B1'-Sub-[Glu<sup>B26</sup>]-des-(B27-B30)-insulin-B26-amide insulin dimer.

Claim 24. (Currently Amended) A pharmaceutical preparation, comprising

- a) an insulin analog as claimed in claim 15, and
- b) a pharmaceutical carrier additions selected from the group consisting of a comprising zinc salt salts, phenol, m-cresol, glycerol, and a buffer substances.

Claim 25. (Currently Amended) A pharmaceutical preparation, comprising

- a) an insulin analogue as claimed in claim 21, and
- b) a pharmaceutical carrier additions selected from the group consisting of a comprising zinc salt salts, phenol, m-cresol, glycerol, and a buffer substances.

Claim 26. (Currently Amended) A pharmaceutical preparation, comprising

- a) an insulin analogue as claimed in claim 22, and
- b) a pharmaceutical composition additions selected from the group consisting of a comprising zinc salt salts, phenol, m-cresol, glycerol, and a buffer substances.

Claim 27. (Currently Amended) A pharmaceutical preparation, comprising

- a) an insulin analogue as claimed in claim 23, and
- b) a pharmaceutical composition ~~additions~~ selected from the group consisting of a ~~comprising~~ zinc salt ~~salts~~, phenol, m-cresol, glycerol, and a ~~buffer substances~~.

Claim 28. (Currently Amended) A method for treating diabetes, comprising administering the pharmaceutical product as claimed in claim 24 to a host that has diabetes.

Claim 29. (Currently Amended) A method for treating diabetes, comprising administering the pharmaceutical product as claimed in claim 25 to a host that has diabetes.

Claim 30. (Currently Amended) A method for treating diabetes, comprising administering the pharmaceutical product as claimed in claim 26 to a host that has diabetes.

Claim 31. (Currently Amended) A method for treating diabetes, comprising administering the pharmaceutical product as claimed in claim 27 to a host that has diabetes.

Claim 32-36 (Canceled).